, /PRNewswire/ -- (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data, today announced a partnership with the Digital Health Measurement Collaborative Community (DATAcc) by the Digital Medicine Society ( ). Cumulus will participate in the DATAcc by DiMe project, which will convene leaders from across the field to establish shared industry benchmarks for evaluating the return on investment (ROI) of digital endpoints in the development of drugs, medical devices, and other regulated interventions. Outputs of the project will include a value framework, industry benchmarking tools, ROI forecasting models, and a modular template to support innovators developing the business case for digital endpoints in the development, implementation, and scale of fit-for-purpose digital measures as endpoints in clinical trials.
"The value of using digital measures in clinical research is significant, but still adopters often struggle to make the case for broader use," said , PhD, Program Director DiMe. "At DiMe, we're committed to advancing the use of digital health measures in research to improve lives, and we value the contribution from key partners like Cumulus Neuroscience to develop resources that will help drive the industry towards increased utilization." Previously, Cumulus participated in the DATAcc by DiMe project, which established the only library specifically focused on industry-sponsored stu.
